Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + interferon-β + nimustine + vincristine
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
This is a multi-agent chemotherapy regimen combining four drugs—carboplatin, interferon-β (IFNβ), nimustine (also known as ACNU), and vincristine. The combination has been studied primarily in the treatment of glioblastoma multiforme, often alongside radiotherapy. - **Carboplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and inhibits DNA synthesis. - **Interferon-β** is an immunomodulatory cytokine with antiproliferative and immune-stimulating effects. - **Nimustine (ACNU)** is a nitrosourea alkylating agent that induces DNA damage by alkylation and carbamoylation of nucleic acids and proteins. - **Vincristine** is a vinca alkaloid that disrupts microtubule formation, inhibiting mitosis in cancer cells. The regimen has demonstrated safety and tolerability in clinical studies for glioblastoma multiforme, with some evidence suggesting it may prolong survival when combined with radiotherapy[1][2].
- Other names
- ACNU-carboplatin-vincristine-IFNβVAC-FERON-R
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on carboplatin + interferon-β + nimustine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + interferon-β + nimustine + vincristine.